Biotech & Life Sciences
Corvus’ Experimental Drug Delivers Strong Results in Hard-to-Treat AD
Corvus Pharmaceuticals (NASDAQ: CRVS) announced encouraging results from cohort 4 of its Phase 1 trial of soquelitinib in moderate to severe atopic dermatitis. The data show good safety and efficacy, similar to earlier cohorts, and suggest longer treatment may improve responses. Cohort 4 Results Cohort 4 included 12 patients on soquelitinib and 12 on placebo.…
The Hidden Investing Risk No One Talks About: Cognitive Decline
Investors spend a lot of time debating valuations, interest rates, and where the next recession might come from. Very little time is spent on something that is arguably just as important over the long run: whether we remain capable of making good financial decisions as we age. That is not a comfortable topic. It also…
Breakthrough: Atossa’s (Z)-Endoxifen Gains FDA Orphan Status for DMD
Atossa Therapeutics (Nasdaq: ATOS) said the FDA granted Orphan Drug Designation for its drug (Z)-endoxifen in Duchenne muscular dystrophy. This follows a prior Rare Pediatric Disease designation. It’s a positive regulatory step. But it does not guarantee approval and it does not make trials any faster. CEO Steven Quay called it an important milestone. He…
One Dose, Months of Relief: Eupraxia’s EoE Breakthrough
Eupraxia Pharmaceuticals (NASDAQ:EPRX) (TSX:EPRX) put out an update on its RESOLVE study this week, and the results look encouraging, at least at this stage. The company shared new tissue and symptom data from patients treated with EP-104GI for eosinophilic esophagitis, a condition that remains difficult to treat long term. What stands out most is how…
Chinese Biotech Growth Forces U.S. Companies to Innovate Faster
David Li, founder of Meliora Therapeutics, quickly learned that the U.S. biotech space isn’t isolated anymore. While looking at drug targets for his new company, he noticed that a lot of the same targets were already being pursued by Chinese firms. Curious, he went to Shanghai and Suzhou. What he saw surprised him. “They’re all…
Eli Lilly Breaks Out with Zepbound, Hits Trillion-Dollar Valuation
Eli Lilly had a breakout year in 2025, largely thanks to its new obesity treatment Zepbound. Alongside its diabetes-focused medication Mounjaro, Lilly’s products outsold all other pharmaceuticals in the first three quarters. The company’s strong sales performance helped it become the first drugmaker to hit a trillion-dollar valuation. Novo Nordisk Racing to Close the Gap…
Monk Fruit Under the Microscope: What Makes It Tick
Monk fruit is usually talked about as a sugar substitute, and that is fair. That is how most people encounter it. The plant, known as Luo Han Guo (Siraitia grosvenorii), comes from southern China and belongs to the same family as squash and cucumbers. It has been used there for a long time, mostly in…
Illumina and Big Pharma Collaborate on Massive Cell Atlas for AI Models
Illumina has unveiled what it calls the largest genome-wide genetic perturbation dataset ever created, aimed at boosting AI-driven drug discovery across the pharmaceutical industry. The new Billion Cell Atlas represents the first phase of a planned five-billion-cell resource that the company expects to complete over the next three years. Illumina says the project will eventually…
New Immune Map Offers Hope for Multiple Myeloma Patients
Scientists are mapping immune cells in the bone marrow of multiple myeloma patients. You could say it’s a way to see how the immune system interacts with cancer cells. It might also help doctors figure out how aggressive the cancer is and guide new immune-based therapies. The study, in Nature Cancer, involved teams from WashU…
New Lung-on-a-Chip Mimics TB Infection in Real Time
Scientists have made a human lung-on-a-chip that mimics the tiny air sacs in the lungs, called alveoli. You could say it’s like a mini-lung in a lab dish. It might help researchers understand how TB infects the lungs and how treatments could work for different people. The study, published in Science Advances, comes from the…
